In the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting regarding asthma, Dr. William Anderson, Associate Professor of Pediatrics at the Children’s Hospital Colorado and the University of Colorado, the United States, discussed electronic medication monitoring (EMM) as part of the session entitled “Improving Adherence Outcomes for the Difficult-to-Treat Asthma Patient”.¹

For decades, the use of SABAs has been recommended both as initial treatment and for symptomatic relief in patients with varying severities of asthma. Recent studies have shown that treatment with inhaled corticosteroids (ICS) reduces the risk of exacerbations when compared to treatment with SABA al

In the latest Global Initiative for Asthma (GINA) 2019 guidelines for adults and adolescent, the most important change in asthma management in 30 years has been made.¹ For safety reasons, GINA no longer recommends treatment with short-acting beta-agonists (SABA) therapy alone.¹ While there is strong evidence that supports

When compared to placebo, the use of masitinib has shown a 35% reduction in severe asthma exacerbation rate (SAER) (RR=0.64, 95% CI: 0.47-0.90; p=0.0103)

First-line asthma therapy requiring inhaled short-acting beta-agonists (SABA) and systemic corticosteroids is well-established and usually effective in most children with mild or moderate exacerbations.¹ However, a minority of children fail to respond and require escalation treatment.¹ With a large